Clinical trial
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of…
NCT00337883 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00337883 |
|---|---|
| Title | A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) |
| Official title | A Phase II, Multicenter, Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma |
| Intervention type | Drug |
| Interventions | Erlotinib HCl (OSI-774) |
| Enrollment | 110 |
| Start date | Jul 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Jun 20, 2006 |
| Last update posted | Mar 4, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: